CefiximeMu

## Report on Cefixime Package Insert Amendment Regarding Mouth Ulceration **1. Executive Summary:** This report analyzes a directive from the Central Drugs Standard Control Organization (CDSCO), Government of India, issued on June 19, 2019, regarding Cefixime. This directive mandates that all manufacturers of Cefixime formulations in India must include "Mouth Ulceration" as an adverse drug reaction in the package insert/promotional literature for the drug. This amendment aims to enhance patient safety by providing more complete information about potential side effects to healthcare professionals and patients. The key finding is that this directive formalizes the inclusion of a previously unlisted adverse reaction based on pharmacovigilance data. **2. Introduction:** The purpose of this report is to provide an informative overview of the CDSCO directive F. No. 120118DC Pt337, dated June 19, 2019, concerning the labeling of Cefixime. The report focuses on the key provisions of this directive, its implications for manufacturers, and the likely impact on patient safety. **3. Policy Overview:** This is an **Amendment** to existing policy regarding the labeling and prescribing information for Cefixime, specifically related to adverse drug reactions. The directive doesn't reference a specific overarching policy being amended; rather, it addresses an element *within* existing regulations about drug labeling. **Core Objective(s):** The core objective of this directive, as inferred from the text, is to: * Enhance patient safety by ensuring complete and accurate information about the potential adverse effects of Cefixime is included in the drug's package insert/promotional literature. * Implement recommendations from the Pharmacovigilance Programme of India (PvPI) based on reported Adverse Drug Reactions (ADRs). **4. Background and Rationale:** This amendment is driven by data collected through the Pharmacovigilance Programme of India (PvPI), indicating a potential link between Cefixime use and the development of mouth ulceration. The National Coordination Centre for PvPI reviewed ADR reports and recommended that CDSCO incorporate mouth ulceration into the prescribing information leaflet (PIL) for Cefixime. The Subject Expert Committee (SEC) deliberated and agreed with this recommendation. Therefore, the amendment addresses the need to update the prescribing information based on new safety signals identified through post-market surveillance. **5. Key Provisions / Changes:** This directive represents an amendment to existing drug labeling requirements for Cefixime. * **Specific part of the original policy being changed:** The amendment modifies the required content of the package insert/promotional literature for Cefixime, specifically the section listing known adverse drug reactions. * **New Rule/Provision:** The new rule mandates that all manufacturers of Cefixime formulations under the jurisdiction of State/UT Drugs Controllers *must* include "Mouth Ulceration" as an adverse drug reaction in the package insert and promotional literature for the drug. * **Difference/Effect of the Change:** Prior to this directive, "Mouth Ulceration" was apparently *not* a listed adverse drug reaction for Cefixime. This change requires manufacturers to actively inform healthcare professionals and patients about this potential side effect. This will likely lead to increased awareness of this specific ADR, potentially resulting in earlier detection, diagnosis, and management of the condition in patients taking Cefixime. **6. Target Audience and Stakeholders:** The primary target audience is: * Manufacturers of Cefixime formulations in India. Secondary stakeholders include: * State/UT Drugs Controllers (responsible for enforcing the directive). * Healthcare professionals prescribing Cefixime. * Patients taking Cefixime. * The National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI). * Subject Expert Committee (SEC) **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The CDSCO is ultimately responsible for the implementation of this directive. State/UT Drugs Controllers are tasked with directing and overseeing the manufacturers within their jurisdiction. * **Timelines/Procedures:** The directive instructs State/UT Drugs Controllers to direct manufacturers to update their packaging and promotional literature. It also requests that the State/UT Drugs Controllers intimate the CDSCO of the actions taken. While a specific deadline is not mentioned, the language ("you are requested to direct...") implies a need for prompt action. It can be inferred that manufacturers need to update the package inserts and promotional literature in a timely manner. * **Implementation aspects related specifically to the changes:** The directive hinges on effective communication from the State/UT Drugs Controllers to the manufacturers. A follow-up mechanism is in place, requesting updates from the State/UT Drugs Controllers to the CDSCO. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is improved patient safety. By explicitly listing "Mouth Ulceration" as an adverse drug reaction, the directive aims to: * Increase awareness among healthcare professionals, enabling them to better monitor patients for this side effect. * Increase awareness among patients, prompting them to report any symptoms of mouth ulceration to their healthcare providers. * Improve the overall understanding of Cefixime's safety profile. * Potentially lead to more informed prescribing decisions and better patient management. **9. Conclusion:** The CDSCO directive mandating the inclusion of "Mouth Ulceration" as an adverse drug reaction in Cefixime package inserts represents a significant step towards enhancing patient safety and ensuring that prescribing information reflects the latest pharmacovigilance data. This amendment requires manufacturers to update their labeling and promotional materials promptly and underscores the importance of ongoing monitoring and evaluation of drug safety. The impact of this change will be felt by manufacturers, healthcare professionals, and ultimately, patients taking Cefixime.

Key Entities Referenced